About Luxsol™ Suspension Solution

Luxsol™ Suspension Solution is one of the treatments in the USA to receive USPTO granted to treat Covid-19 virus and Influenza.

Luxsol™ Suspension Solution is a new drug. It is Patented by the US Patent Office; US Pat. No. 16/881,937 on January 7th, 2021 – for the treatment of COVID-19 and Influenza.

Luxsol Suspension Solution

What is Luxsol™ Suspension Solution? Luxsol Suspension Solution is a targeted therapeutic therapy treatment for Respiratory illness associated with Covid-19 and influenza. It is not a pill or an injection. It is a spray through the mouth and directly to lungs using a nebulizer.

Side Effects

None. No known side effects.

History of Luxsol suspension solution

  • May 22nd, 2020 Prioritized Examination Pilot Program started. Luxsol Suspension Solution Patent Application was submitted
  • June 4th, 2020 Granted Prioritized Examination Status as part of USPTO to treat Covid-19 and Influenza.
  • January 7th, 2021 3V Medical Research Group was notified of the approval of the application to treat Covid-19 and Influenza (Patent approved within 7 months)

Luxsol Suspension Solution was successfully tested in treatment of Covid-19 in a In Vitro Study using Remdesivir as the positive Control. Results were equally effective to kill the SARS-COV-2 as Remdesivir.

In Vitro Study SOW (click here)
Final In Vitro Study test report (click here)

In Vivo Study,  Safety/Toxicity results (click here)

Luxsol Suspension Solution is one of the treatments in the USA to receive USPTO granted to treat Covid-19 virus and Influenza.

3V Medical Research Group developed Luxsol™ Suspension Solution as a targeted therapeutic therapy to treat Covid-19.